Ondine Biomedical, Inc.LSE: OBI

Completion of Nominated Adviser due diligence

· Issued by Ondine Biomedical, Inc.
Watch Ondine Biomedical explain itONDINE BIOMEDICAL INC. (OBI) — Investor Presentation of Phase 3 Topline Results · Replay · Sep 10

26 July 2022                                           

Ondine Biomedical Inc.

("Ondine Biomedical", "Ondine" or the "Company")

Completion of Nominated Adviser due diligence

Ondine Biomedical Inc. (AIM: OBI) announces that Strand Hanson Limited, appointed as the Company's Nominated Adviser on 27 April 2022, has confirmed completion of its due diligence.

Pursuant to Schedule 2(g)(ii) of the AIM Rules for Companies, the following disclosures are required:

Director

Current directorships

Carolyn Cross

12673011 Canada Inc.

Nicolas Loebel

Advanced Photodynamic Technologies Inc.

Axcess Medical Inc.

Ondine Research Laboratories Ltd

For more information, please visit: www.ondinebio.com or contact: 

Ondine Biomedical Inc. 

Carolyn Cross, CEO   +001 (1) 604 669 0555

Strand Hanson Limited (Nominated and Financial Adviser)

Richard Johnson, James Harris, James Dance                                                               +44 (0) 20 7409 3494

Arden Partners plc (Broker)

Ruari McGirr    +44 (0) 20 7614 5900

Vane Percy & Roberts (Media Contact)

Simon Vane Percy, Amanda Bernard                                                                              +44 (0) 77 1000 5910